natgillin/translations-raw huggingface dataset:
The subject of the invention is therefore a cast part with high mechanical resistance and hot creep strength, in particular around 300° C. or even above, combined with a high yield strength at ambient temperature and high low cycle and high cycle mechanical fatigue strength, and with good ductility from ambient temperature up to 300° C., made of aluminum alloy of chemical composition, expressed in percentages by weight: 
HR P20170809T PATENTNI ZAHTJEVI Lijevani komad s jakom statičkom mehaničkom čvrstoćom, te s izdržljivošću na zamor materijala i na visoke temperature, posebno na 300"€, naznačen time, da je izrađen od aluminijske legure čiji je kemijski sastav izražen u masenim postotcima, kako slijedi:
is hydrogen or together with R7 is an a or B -CH2 group; 
je vodik ili zajedno s R7 je a ili B -CH2 skupina;
An LED module of claim 9, wherein said module circuit includes a thermistor to sense the temperature of the LED. 
LED modul iz patentnog zahtjeva 24, naznačen time, da navedeni sklop modula sadržava termistor koji odčitava temperaturu LED diode.
The in vitro diagnostic method of any one of claims 1 to 21, comprising providing a uterine fluid sample obtained from a patient with a pipelle device or syringe wherein the patient has a risk factor or symptom of endometrial cancer; 
Postupak dijagnosticiranja in vitro u skladu s bilo kojim od patentnih zahtjeva 1 do 15 i 17 do 20, naznačen time što se sastoji u osiguravanju uzoraka maternične tekućine uzetog iz pacijentice uz pomoć pipele ili injekcijske šprice, gdje pacijentica posjeduje čimbenik rizika ili pokazuje simptom raka endometrija;
Particular advantages of the L-lactate salt of the compound of formula (1) are that it: 
HR P20180375 T1 PATENTNI ZAHTJEVI Kombinacija koja sadrži kiselinsku adicijsku sol spoja formule (1) o
A peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises the amino acid sequence of SEQ ID NO: 376 or 379. 
Izolirani peptid od manje od 15 aminokiselina koja može inducirati citotoksične T-stanice, naznačen time što se navedeni peptid bira iz skupine koju čine peptidi koji sadrže aminokiselinski slijed SEQ ID NO: 30, 19, 22, 34 ili 358.
said stabilizing agent is 2% w/v sucrose; and said surfactant is 0.004% w/v polysorbate-20; lyophilizing said therapeutic peptibody. 
navedeni stabilizator je 2% w/v saharoza; i navedena površinski aktivna materija je 0.004% w/v polisorbat-20; ili
in said extrusion head (2) the simultaneous extrusion of the formed second mixture with the first mixture so that the polymer at least partially encloses the said particles; whereby, on the basis of the formed second mixture, a first layer (4) is formed on the plastic strand (3), which first layer shall at least partially cover the outer surface of this plastic strand (3). 
u navedenoj ekstruzijskoj glavi (2) istodobnog ekstrudiranja dobivene druge smjese s prvom smjesom, tako da polimer u najmanju ruku djelomično oblaže navedene čestice; gdje se, na osnovi dobivene druge smjese, načini prvi sloj (4) na plastičnoj niti (3), gdje će navedeni prvi sloj u najmanju ruku djelomično pokriti vanjsku površinu te plastične niti (3).
It is well known that these compounds are readily soluble in water and the biological activity of their pharmacologically acceptable salts usually does not differ from that of the initial compound. 
Dobro je poznato da se ti spojevi odmah tope u vodi i da se biološko djelovanje njihovih farmakološki prihvatljivih soli obične ne razlikuje od polaznog spoja.
Just as particular considerations are required with regard to how the filling medium is introduced, preferably as a liquid, into the groove structures 4 before the separation operation proceeds, particular considerations are required with regard to how the filling medium situated in the groove structures 4 is removed again after mechanical machining. 
Kao što su prije provedbe postupka odvajanja potrebna posebna razmatranja što se tiče načina uvođenja punila u brazdaste strukture 4, ponajprije kao tekućine, jednako tako su nakon mehaničke strojne obrade potrebna i posebna razmatranja u pogledu načina ponovnog odstranjivanja punila koje se nalazi u brazdastim strukturama 4.
A pharmaceutical composition comprising a compound of any one of claims 1 to 11, a compound of Formula IX: or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable carrier. 
Farmaceutska kompozicija sadrži spoj sa formulom IX: [image] ili njegova farmaceutski prihvatljiva sol ili ester i njegov farmaceutski prihvatljivi nosač.
The present invention relates to new combinations of certain antimuscarinic agents with corticosteroids and their use in the treatment of respiratory disorders. 
Predmetni se izum odnosi na nove kombinacije određenih antimuskarinskih lijekova s fB-adrenergičkim agonistima i njihovu uporabu u liječenju respiratornih poremećaja.
The method according to claim 1, wherein the aclidinium is in the form of aclidinium bromide. 
Aklidinij za primjenu prema zahtjevu 1, naznačen time, što se aklidinij nalazi u obliku aklidinijevog bromida.
The torpedo of claim 1, wherein the torpedo is heated using an external heat source. 
Torpedo prema zahtjevu 1, naznačen time da se torpedo zagrijava korištenjem vanjskog izvora topline (97).
cooling said heated suspension of (b) from a temperature in said first temperature range to a temperature in said second temperature range; and 
hlađenje navedene zagrijane suspenzije (b) od temperature u navedenom prvom temperaturnom rasponu do temperature u navedenom drugom temperaturnom rasponu; i
Security element according to one of claims 1 to 8, further comprising marking means selected from the group consisting of infrared markers, fluorescent markers, UV markers, phosphorescence markers, magnetic markers, forensic markers and mixtures thereof. 
Sigurnosni element prema jednom zahtjevu od 1 do 7, naznačen time da dodatno sadrži sredstva za označavanje odabrana iz skupine koja sadrži infracrvene markere, fluorescentne markere, UV markere, fosforescencijske markere, magnetske markere, forenzične markere i njihove smjese.
adding n-heptane to the first mixture at a temperature from about 40 °C to about 70 °C to form a second mixture; and 
(b) dodavanja n-heptana ovoj primarnoj smjesi, na temperaturi od 40*%€ do 70"C, uz nastanak sekundarne smjese; i
Furthermore, the volume of the filter cake can be decreased significantly. A process for the purification of water comprising obtaining a surface-treated natural calcium carbonate that was prepared by treating a natural calcium carbonate from a natural source that is not saturated with heavy metals with an acid and carbon dioxide in water to obtain surface-treated natural calcium carbonate, wherein the carbon dioxide is formed in situ and/or supplied externally, and wherein the surface-treated natural calcium carbonate has a specific surface area of from 5-200 m2/g as measured using nitrogen and BET method; 
PATENTNI ZAHTJEVI Postupak za pročišćavanje vode, gdje se površinski-reagirani prirodni kalcij karbonat dovodi u kontakt sa vodom koju se treba pročistiti, pri čemu je površinski-reagirani prirodni kalcij karbonat produkt reakcije prirodnog kalcij karbonata sa kiselinom i ugljičnim dioksidom, koji je stvoren in situ pomoću tretmana kiselinom i/ili uveden izvana, te se površinski-reagirani prirodni kalcij karbonat priprema kao vodena suspenzija sa pH većim od 6.0, mjereno pri 20%C, te se dodaje polimerni flokulant u vodu koju se treba pročistiti nakon dodatka površinski-reagiranog prirodnog kalcij karbonata.
The composition for use according to claim 9, wherein the composition is administered orally; and wherein said composition further comprises cow's milk, human breast milk, infant formula or water. 
dC ili dT, namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što se pripravak primjenjuje oralno; te što navedeni pripravak dodatno sadrži kravlje mlijeko, majčino mlijeko, formulu za dojenčad ili vodu.
the double stranded RNAi agent is to be administered at a dose of about 0.01 mg/kg to about 10 mg/kg, about 0.5 mg/kg to about 50 mg/kg, or about 10 mg/kg to about 30 mg/kg; and/or 
dvolančano RNAi sredstvo se treba primjenjivati u dozi od oko 0.01 mg/kg do oko 10 mg/kg, oko 0.5 mg/kg do oko 50 mg/kg, ili oko 10 mg/kg do oko 30 mg/kg; i/ili
A crystal of 2-{-4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Ka radiation. 
Kristalni oblik 2-(4-[N-(5,6-difemlpirazin-2-11)-N-izopropilaminojbutiloksi)-N-(metilsulfoniljacetamida, naznačen time što pokazuje difrakcijske maksimume u svom spektru difrakcije rendgenskih zraka na prahu, u najmanju ruku pod sljedećim kutovima difrakcije 20: 9,4 stupnjeva, 9,8 stupnjeva, 17,2 stupnjeva i 19,4 stupnjeva, gdje je dijagram difrakcije rendgenskih zraka na prahu dobiven zračenjem Cu K..
In a particularly preferred embodiment of the invention the external portion of the adjuster mandrel includes a jar as defined hereinabove; the external portion of the adjuster mandrel includes a collar that is moveable relative to the remainder of the adjuster mandrel and has a protuberance that is engageable with a shoulder defined in the hollow housing; and the adjuster mandrel includes a threaded portion having threadedly engaged therewith a lock nut that on tightening engages the collar to force the protuberance into engagement with the shoulder and thereby prevent operation of the adjuster. 
U posebno preporučenom primjeru prema izumu vanjski dio vretena podešivača sadrži ogrlicu koja se može pomicati u odnosu na ostatak vretena podešivača i ima ispupčenja koja su zahvaćena ramenom, koji je u šupljem kućištu, i što vreteno podešivača sadrži dio s navojem koji je navojem u vezi s navrtkom za zabravljivanje, koji pritezanjem zahvaća ogrlicu da potisne ispupčenja u sklop s ramenom i time spriječi rad podešivača.
The antibody, functional fragment thereof or antibody mimetic for use according to any one of claims 1 to 3, wherein the antibody, functional fragment thereof or antibody mimetic is a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody. 
4. Antitijelo, njegov funkcionalni fragment ili mimetik antitijela za primjenu prema bilo kojem od zahtjeva 1 do 3, pri čemu je antitijelo, njegov funkcionalni fragment ili mimetik antitijela kimerično antitijelo, humano antitijelo, humanizirano antitijelo, jednolančano antitijelo, defukolizirano antitijelo ili bispecifično antitijelo.
A study was carried out in rats to determine whether the dihydrotetrabenazine isomers of the invention have sedative properties. 
Na štakorima je bilo provedeno proučavanje da bi se odredilo imaju li dihidrotetrabenazin izomeri izuma sedativna svojstva.
preparing a solution of KGF in a concentration between 3 mg/mL and 15 mg/mL; the buffer histidine; mannitol at a concentration of 2% to 5% w/v; sucrose at a concentration of 1% to 3% w/v; polysorbate 20 at a concentration within a range of 0.004% to 0.1% w/v, wherein the pH is in a range of 6.0 to 8.0; and 
pripreme otopine KGF u koncentraciji između 3 mg/mL i 15 mg/mL; histidina kao pufera; manitola u koncentraciji od 2% do 5% tež./vol.; saharoze u koncentraciji od 1% do 3% tež./vol.; polisorbata 20 u koncentraciji unutar opsega od 0.004% do 0.1% tež./vol., pri čemu je pH u opsegu od 6.0 do 8.0; i
The netrin-1 binding monoclonal antibody of any one of claim 8 to 11, which comprises an amino acid sequence selected from the group of SEQ ID NO: 14 to 19 and/or from the group of SEQ ID NO: 20 to 27, preferably it comprises an amino acid sequence selected from the group of SEQ ID NO: 14 to 19 and an amino acid sequence selected from the group of SEQ ID NO: 20 to 27. 
Monoklonsko protutijelo koje veže netrin-1 prema bilo kojem od zahtjeva 8 do 11, naznačeno time što sadrži aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 14 do 19 i/ili iz skupine SEQ ID NO: 20 do 27, poželjno sadrži aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 14 do 19 i aminokiselinsku sekvencu odabranu iz skupine SEQ ID NO: 20 do 27.
A method for controlling undesired plants or inhibiting their growth, which comprises applying a herbicidally effective amount of the pyrazole compound or its salt as defined in claim 1, to the undesired plants or to a place where they grow. 
Postupak za kontroliranje nepoželjnih biljaka ili sprječavanje njihovog rasta, naznačen time, da isti sadrži primjenu herbicidno učinkovite količine spoja pirazola ili njegove soli definirane u patentnom zahtjevu 1 ili 2 na nepoželjne biljke ili na mjesto njihovog rasta.
An example of a linker as defined herein is depicted in Figure 3. 
Primjer veznika, kako je ovdje definiran, prikazan je na slici 3.
The method of any preceding claim wherein the compound 1 c is selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine:
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 to 5, preferably wherein said antigen-presenting cell comprises an expression vector expressing said peptide according to any one of claims 1 to 5. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2,pri čemu opcionalno stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
The antibody of item 2, wherein the antibody comprises a heavy chain consisting of the amino acid sequence ranging from the 20th amino acid (glutamic acic.) to the 466th amino acid (lysine) of SEQ ID NO: 7 and a light chain consisting of the amino acid sequence ranging from the 23th amino acid (aspartic acid) to the 236th amino acid (cysteine) of SEQ ID NO: 8. 
Konjugat antitijela i lijeka prema patentnom zahtjevu 1, gdje antitijelo sadrži teški lanac koji se sastoji od ostatka amino kiseline 20 do ostatka amino kiseline 466 sekvence SEQ ID NO: 7 te laki lanac koji se sastoji od ostatka amino kiseline 23 do ostatka amino kiseline 236 sekvence SEQ ID NO: 8.
Process according to claim 1, wherein the standard deviation of the particle size is less than 12% of the mean particle size. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je standardno odstupanje veličine čestica manje od 12% srednje veličine čestica.
ceftriaxone sodium in an amount of 2 g, calculated as ceftriaxone free acid, 
(a) ceftriakson natrij u količini od 2 g, preračunato kao ceftriaksonska slobodna kiselina,
In some embodiments, there is provided a method of treating a recurrent cancer (such as a recurrent gynecological cancer for example recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising a taxane (such as paclitaxel) and a carrier protein (such as albumin), wherein the individual has received prior platinum-based chemotherapy and has a treatment free interval for more than about any of 3, 6, 9 months prior to the initiation of the treatment method with the taxane nanoparticle composition. 
HR P20131142 T1 PATENTNI ZAHTJEVI Pripravak koji što sadrži nanočestice koje sadrže taksan i protein-nosač, naznačen time što je namijenjen upotrebi u postupku liječenja recidiva raka jajnika, peritoneuma ili jajovoda kod osobe, gdje je osoba prethodno primila kemoterapiju i ima interval bez liječenja dulji od otprilike tri mjeseca prije početka liječenja, gdje je taksan paklitaksel, a gdje je protein-nosač albumin.
The polypeptide of claim 1, wherein the polypeptide has at least 95% or at least 99% sequence identity to the amino acid sequence of SEQ ID NO: 1. 
Polipeptid prema patentom zahtjevu 1, naznačen time da polipeptid ima barem 95% ili barem 99% identiteta sekvence od amino kiselinske sekvence od SEQ ID NO: 1.
For example ethylene vinyl acetate (EVA), low density polyethylene (LDPE) and polypropylene (PP). 
Na primjer, etilen vinil acetat (EVA), polietilen male gustoće (LDPE) i polipropilen (PP).
The end point of the curing step is defined to be (1) the point in time when the heating is stopped or at least reduced and the inlet air temperature subsequently drops below the curing temperature by more than about 10 °C and/ or below the lower limit of the softening temperature range of high molecular weight polyethylene oxide, for example below about 62 °C, in a plateau-like temperature profile or (2) the point in time when the inlet air temperature drops below the curing temperature in a parabolic or triangular temperature profile. 
Postupak prema zahtjevu 15, naznačen time da je temperatura u koraku c) definirana kao ciljana ulazna temperatura zraka i gdje korak stvrdnjavanja započinje kada ulazna temperatura zraka dostigne navedenu temperaturu i gdje korak stvrdnjavanja završava ili kada se zaustavi zagrijavanje ili kada je barem smanjeno te ulazna temperatura zraka naknadno pada ispod navedene temperature za više od oko 10 "C ili ispod oko 62 *C, u tr> to HR P20090688 T1 temperaturnom profilu nalik platou ili kada ulazna temperatura pada ispod navedene temperature u paraboličnom ili trokutastom temperaturnom profilu.
The frustoconical- or truncated pyramid-shaped support structure formed by several precast concrete panels according to claim 1, characterized in that the panels (1) have a thickening in the upper portion having a thickness at least twice the minimum thickness of the panel on which a steel tower is coupled by means of a hollow cylinder-shaped transition part of a mixed steel-concrete composition, in which its height is less than half its outer diameter and its wall thickness is at least twice the minimum thickness of the precast panels forming the support structure. 
Nosiva struktura u obliku krnjeg stošca - ili u obliku krnje piramide formirana od nekoliko predgotovljenih betonskih panela prema svim prethodnim zahtjevima, naznačena time da paneli (1) u gornjem dijelu imaju zadebljanje koje ima debljinu najmanje dva puta minimalne debljina panela na koji je spojen čelični toranj pomoću prijelaznog dijela u obliku šupljeg cilindra koji je mješovitog sastava čelik-beton, čija visina je manja od polovine svog vanjskog promjera a debljina njegove stjenke je najmanje dva puta minimalne debljina predgotovljenih panela koji tvore potpornu strukturu.
The chemistry for the preparation of the compounds of this invention is known to those skilled in the art. 
Postupak za pripremu spoja prema patentnom zahtjevu 1, naznačen time što sadrži:
The antibody of any one of claims 1-3 which is a monoclonal, chimeric, human or humanized antibody, or a fragment of an antibody. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-3 koje je monoklonsko, himerno, humano ili humanizirano antitijelo, ili fragment antitijela.
A method as claimed in claim 6, wherein the amount of modified starch in the stabiliser composition is 16 to 35% by dry weight. 
Postupak prema patentnom zahtjevu 6, naznačen time što je količina modificiranog škroba u kompoziciji stabilizatora 16 do 35% prema suhoj težini.
The cooking aid of claim 1, wherein the vegetable or animal fat is selected from the group consisting of pork fat, tallow, lard, bone fats, butter, fractionated palm fat, any fully or partially hydrogenated or inter-esterified palm oil, cotton seed oil, peanut oil, soya oil, olive oil, sunflower oil, rape seed oil, and mixtures thereof. 
Kuhinjsko pomagalo u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što se mast bira iz skupine koju čine svinjska mast, loj, salo, koštane masti, maslac, frakcionirana palmina mast, te bilo koje posve ili djelomično hidrogenirano ili interesterificirano palmino ulje, ulje pamukovog sjemena, kikirikijevo ulje, sojino ulje, maslinovo ulje, suncokretovo ulje ili repičino ulje.
The polymyxin derivative of claim 53, wherein said derivative has three positive charges at physiological pH. 
gdje taj derivat ima tri pozitivna naboja pri fiziološkom pH, i njegovi farmaceutski prikladni prolijekovi i soli.
Bevacizumab for use of claim 1, wherein said treatment further improves said patient's objective response rate (ORR) as compared to a platinum-resistant ovarian cancer patient receiving paclitaxel alone. 
Bevacizumab za uporabu prema patentnom zahtjevu 1, naznačen time, da spomenuti tretman poboljšava objektivnu stopu odgovora spomenute pacijentice (ORR - eng. objective response rate) u usporedbi s pacijenticom koja ima karcinom jajnika otporan na platinu, a koja prima samo paklitaksel.
an antibody VH domain comprising a CDR1 having the amino acid sequence GYTMN (SEQ ID NO:10), a CDR2 having the amino acid sequence LINPYNGGTSYNQNFKG (SEQ ID NO:11) and a CDR3 having the amino acid sequence EDYDGYLYFAMDY (SEQ ID NO:12), wherein the antibody or antigen binding fragment thereof has a binding affinity for IL-25 that is less than or equal to 53pM as determined in a Biacore assay. 
VH domenu protutijela koja sadrži CDR1 aminokiselinske sekvence GYTMN (SEQ ID NO:10), CDR2 aminokiselinske sekvence LINPYNGGTSYNQNFKG (SEQ ID NO:11) i CDR3 aminokiselinske sekvence EDYDGYLYFAMDY (SEQ ID NO:12), naznačeno time da protutijelo ili njegov fragment koji veže antigen izražavaju afinitet vezanja za IL-25 koji je manji ili jednak 53 pM što je utvrđeno upotrebom Biacore testa.
ii) the amount of solubilizer is from about 0.5 to about 26.5% vol, preferably from about 2.0 to about 22.4% vol; and/or 
Tekući sastav za upotrebu prema zahtjevu 1, pri čemu je količina solubilizatora od oko 0,5 do oko 26,5% zap, poželjno od oko 2,0 do oko 22,4 % zap.
The present invention is in the field of cultivation of mammalian cells under serum-free culture conditions. 
Ovaj izum ulazi u područje uzgoja stanica sisavaca u uvjetima kulture stanica bez primjene seruma.
The process according to claim 1 wherein Compound H is reacted with Cbz-L-alanine in the presence of THF or ethyl acetate and a coupling agent at −5 to 5° C. to afford Compound J, which is then deprotected to afford Compound I. 
Postupak prema zahtjevu 1 gdje Spoj H reagira s Cbz-L-alaninom u prisutnosti THF-a ili etil acetata 1 sredstva za vezanje na -5 do 5?C da se dobije Spoj J, s kojeg se zatim uklanja zaštita da se dobije Spoj I. .
A plant according to any of claims 5-7, characterized by further comprising intermediate cooling means (5, 5') between the rolling stands (4). 
Postrojenje iz patentnih zahtjeva 5 - 7, naznačeno time što, pored prethodno navedenih elemenata, sadrži i elemente za međuhlađenje (5, 5%) koji su postavljeni između valjačkih stanova (4).
in part (e), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:121 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:120; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 121 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 120;